Fig. 3: ALPK2 knockdown inhibited bladder cancer development in vivo.
From: ALPK2 acts as tumor promotor in development of bladder cancer through targeting DEPDC1A
A Twenty days of post-injection of T24 cells with or without ALPK2 knockdown, the volume of tumors formed in mice was measured and calculated at indicated time intervals. B In vivo imaging was performed to evaluate the tumor burden in mice of shALPK2 and shCtrl groups at day 22 of post-tumor-inoculation. The fluorescence intensity was scanned and used as a representation of tumor burden in mice of shALPK2 and shCtrl groups. C, D Mice were sacrificed at day 22 of post-injection, and the tumors were removed for collecting photos (C) and weighing (D). E The expression of Ki67 and ALPK2 in tumors removed from mice of both groups was detected by IHC analysis (scale bar = 50 μm in 200 magnification, scale bar = 20 μm in 400 magnification). Data were shown as mean ± SD. ***P < 0.001.
